Thompson C D, Kinter M T, Macdonald T L
Chemistry Department, University of Virginia, Charlottesville 22901, USA.
Chem Res Toxicol. 1996 Dec;9(8):1225-9. doi: 10.1021/tx9601566.
We propose that 3-carbamoyl-2-phenylpropionaldehyde is an intermediate in the metabolism of felbamate, an anti-epileptic drug with a unique profile of the therapeutic activity, and undergoes a cascade of chemical reactions responsible for the toxic properties of the parent drug. To test this hypothesis, we have synthesized 3-carbamoyl-2-phenylpropionaldehyde and evaluated its in vitro reactivity. This molecule was found to be highly unstable at physiological pH (t1/2 < or = 30 s) and to undergo facile elimination to 2-phenylpropenal, an alpha, beta-unsaturated aldehyde commonly termed atropaldehyde. However, the predominant reaction pathway for 3-carbamoyl-2-phenylpropionaldehyde was reversible cyclization to generate 4-hydroxy-5-phenyltetrahydro-1,3-oxazin-2-one, a urethane that has a considerably longer half-life at physiological pH (t1/2 > or = 5 h) and may serve as a stable reservoir of the reactive aldehyde both in vitro and in vivo. Atropaldehyde is a potent electrophile and was found to exhibit cytotoxicity to cultured fibroblasts (50% growth inhibition (GI50) = 4.1 +/- 1.1 microM) comparable to the known unsaturated aldehyde toxins, 4-hydroxy-2-nonenal and acrolein. 3-Carbamoyl-2-phenylpropionaldehyde also exhibited significant cytotoxicity (GI50 = 53 +/- 8 microM), whereas 2-phenyl-1,3-propanediol monocarbamate (GI50 > 500 microM) and 3-carbamoyl-2-phenylpropionic acid (GI50 > 500 microM) were nontoxic. We have additionally demonstrated the formation of a glutathione-atropaldehyde conjugate from the in vitro incubation of 3-carbamoyl-2-phenylpropionaldehyde with glutathione. Thus, the potent cytotoxicity and potential allergenicity of atropaldehyde implicate this unsaturated aldehyde as a possible causative agent in the toxicities observed with felbamate treatment.
我们提出3-氨基甲酰基-2-苯基丙醛是抗癫痫药物非氨酯代谢过程中的一个中间体,非氨酯具有独特的治疗活性,该中间体经历一系列化学反应,这些反应导致了母体药物的毒性。为了验证这一假设,我们合成了3-氨基甲酰基-2-苯基丙醛并评估了其体外反应活性。发现该分子在生理pH值下高度不稳定(半衰期t1/2≤30秒),并容易消除生成2-苯基丙烯醛,一种通常称为阿托醛的α,β-不饱和醛。然而,3-氨基甲酰基-2-苯基丙醛的主要反应途径是可逆环化生成4-羟基-5-苯基四氢-1,3-恶嗪-2-酮,一种氨基甲酸酯,其在生理pH值下具有长得多的半衰期(t1/2≥5小时),并且在体外和体内都可能作为活性醛的稳定储存库。阿托醛是一种强亲电试剂,发现其对培养的成纤维细胞具有细胞毒性(50%生长抑制(GI50)=4.1±1.1微摩尔),与已知的不饱和醛毒素4-羟基-2-壬烯醛和丙烯醛相当。3-氨基甲酰基-2-苯基丙醛也表现出显著的细胞毒性(GI50=53±8微摩尔),而2-苯基-1,3-丙二醇单氨基甲酸酯(GI50>500微摩尔)和3-氨基甲酰基-2-苯基丙酸(GI50>500微摩尔)无毒。我们还证明了3-氨基甲酰基-2-苯基丙醛与谷胱甘肽在体外孵育时形成了谷胱甘肽-阿托醛缀合物。因此阿托醛的强细胞毒性和潜在致敏性表明这种不饱和醛可能是在非氨酯治疗中观察到的毒性的致病因素。